On Monday, Citigroup Inc (NYSE:C)’s shares inclined 0.89% to $50.74.
Citi declared Citi Bike® for Good, a month-long initiative enabling Citi Bike riders to support three of New York City’s most impactful not-for-profit organizations when they ride. Between September 16 and October 16, every Citi Bike ride will support the American Red Cross, No Kid Hungry® and the YMCA of Greater New York. During Citi Bike for Good, hundreds of specially-branded bicycles will hit the streets. Citi will kick off the activation with a base donation of $10,000 for each charity and will follow with up to $40,000 in additional donations to the respective organizations based on ridership during the initiative.
During Citi Bike for Good, any Citi Bike ride – on a specially branded bicycle or a traditional Citi Bike bicycle – will be counted toward the program’s aim of surpassing total riders during the same period in 2014 – 1 million rides. If the aim is met, Citi will contribute an additional $25,000 to each not-for-profit organization. Citi will host additional Pulse Ridership Challenges to encourage overall participation. These challenges will be worth a bonus of $5,000 per organization if the aims are met, resulting in an additional possible $15,000 total donation. The specific ridership aims for the Pulse Ridership Challenges will be declared during the month. The challenges will comprise:
- Super Commuters Challenge:Rides in a work week, September 21 - September 25
- Weekend Warrior Challenge:Rides in a weekend, October 3 and October 4
- Interborough Explorers Challenge:Borough-to-borough rides, October 7 - October 11
Citigroup Inc., a diversified financial services holding company, provides various financial products and services for consumers, corporations, governments, and institutions worldwide. The company operates through two segments, Global Consumer Banking (GCB) and Institutional Clients Group (ICG).
Texas Instruments Incorporated (NASDAQ:TXN)’s shares dropped -0.73% to $47.45.
Texas Instruments Incorporated (TI) (TXN) said it will raise its quarterly cash dividend by 12 percent, from $0.34 per share to $0.38, or $1.52 annualized. The higher dividend will be payable November 16, 2015, to stockholders of record on October 30, 2015, contingent upon formal declaration by the board of directors at its regular meeting in October.
The board of directors also authorized the company to repurchase an additional $7.5 billion of its common stock over time. This is in addition to about $1.8 billion of formerly authorized repurchases that remained at the end of June 2015.
Dividend enhances and share repurchases are both part of TI’s capital administration strategy. The company has raised dividends each year for the past 12 years, and through comprising share repurchases has reduced outstanding shares by 40 percent since the starting of 2005.
Texas Instruments Incorporated designs, manufactures, and sells semiconductors to electronics designers and manufacturers worldwide. It operates through two segments, Analog and Embedded Processing.
At the end of Monday’s trade, Allergan PLC (NYSE:AGN)‘s shares dipped -3.30% to $285.55.
Allergan plc (AGN) and Gedeon Richter Plc. declared that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR™ (cariprazine) capsules, an atypical antipsychotic, for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for treatment of schizophrenia in adults.
Bipolar I disorder and schizophrenia are chronic and disabling mental health disorders. Bipolar I disorder, also known as manic-depressive illness, is a disorder of the brain that is characterized by fluctuations in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Schizophrenia is characterized by delusions, hallucinations, disorganized speech and behavior, and other symptoms that cause social or occupational dysfunction.
The FDA approval of VRAYLAR is based on the results of three 3-week controlled trials in adults with manic or mixed episodes of bipolar I disorder and three 6-week placebo-controlled trials in adults with schizophrenia. In these clinical trials involving more than 2,700 adults, VRAYLAR demonstrated improvement contrast to placebo as measured by Young Mania Rating Scale (YMRS) total scores in patients with bipolar mania and by Positive and Negative Syndrome Scale (PANSS) total scores in patients with schizophrenia. VRAYLAR also demonstrated efficacy as measured by the Clinical Global Impressions-Severity (CGI-S) rating scale, the secondary efficacy endpoints for both conditions.
Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution.
Devon Energy Corp (NYSE:DVN), ended its Monday’s trading session with 1.38% gain, and closed at $40.33.
Devon Energy Corp. (DVN) declared that its board of directors declared a quarterly cash dividend on Devon’s common stock for the fourth quarter of 2015. The dividend is payable on Dec. 31, 2015, at a rate of $0.24 per share based on a record date of Dec. 15, 2015.
Devon Energy Corporation, an independent energy company, primarily engages in the exploration, development, and production of oil, natural gas, and natural gas liquids (NGLs) in the United States and Canada.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
